Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Rezolute, Inc. (Nasdaq:RZLT) will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020. CEO Nevan Charles Elam will lead the presentation, accessible through the conference's recording library. Additionally, Rezolute will conduct 1x1 meetings, available upon request. The company focuses on developing targeted therapies for rare and metabolic diseases, with its lead asset RZ358 in Phase 2b for congenital hyperinsulinism. RZ402 is also set to enter clinical trials for diabetic macular edema.
- None.
- None.
REDWOOD CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that Nevan Charles Elam, the Company’s CEO and founder, will be presenting a corporate overview as part of the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning November 23, the presentation will be available for viewing anytime through December 3 by accessing the recording library on the Piper Sandler conference site.
Rezolute will also be participating in 1x1 meetings which can be requested via Piper Sandler.
About Rezolute, Inc.
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for congenital HI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor which is staged to transition into clinical development for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
FAQ
When is Rezolute's presentation at the Piper Sandler Healthcare Conference?
Who is presenting on behalf of Rezolute at the conference?
What is the focus of Rezolute, Inc.?
What is RZ358 and its current development stage?
What is RZ402's purpose and status?
